Dr. Deitel studies sarcoma, a challenging type of cancer that affects tissues such as muscle, fat, and bone. His research specifically investigates how a hormone called IGF-I (Insulin-like Growth Factor 1) influences the growth of sarcoma tumors. By looking at mice that lack IGF-I, he has been able to show that their tumors grow more slowly than those in normal mice. This finding is significant because it opens the door to new potential treatment strategies that could target the IGF-I pathway to help control sarcoma growth and improve patient outcomes.
Key findings
In 5 out of 8 types of sarcoma studied, tumors grew more slowly in mice lacking the IGF-I hormone compared to normal mice.
The research indicates a clear link between IGF-I levels and tumor growth, demonstrating the potential for targeting this pathway in treatment.
The findings suggest that manipulating IGF-I could lead to novel treatment strategies for patients with various sarcoma types.
Frequently asked questions
Does Dr. Deitel study sarcoma?
Yes, Dr. Deitel specializes in researching sarcoma and its growth mechanisms.
What treatments has Dr. Deitel researched?
He explores treatment strategies that target the IGF-I hormone to potentially slow down sarcoma tumor growth.
Is Dr. Deitel's work relevant to patients with cancer?
Yes, his research on IGF-I and sarcoma may lead to new treatment options for patients with this type of cancer.
Publications in plain English
Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation.
2002
Journal of surgical oncology
Deitel K, Dantzer D, Ferguson P, Pollak M, Beamer W +2 more
Plain English This study looked at how a lack of a hormone called IGF-I affects the growth of human sarcoma tumors in mice. The researchers found that in 5 out of 8 types of sarcoma, tumors grew more slowly in mice that lacked IGF-I compared to normal mice. This is important because it highlights that targeting the IGF-I pathway could potentially slow down tumor growth in these cancers.
Who this helps: This helps patients with sarcoma by suggesting new treatment strategies.